文献速递胸部肿瘤放疗

治疗前免疫状态可预测接受化放疗联合度伐利尤单抗治疗的非小细胞肺癌患者的疾病控制

Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab.
PubMed 文献 · Radiother Oncol · 2021-12-20

该研究在113例接受同步化放疗(cCRT)并至少接受1剂度伐利尤单抗的III期非小细胞肺癌(NSCLC)患者中,评估外周血免疫指标及两个已发表模型估算的免疫器官放疗剂量风险评分与疾病控制的关系。中位无进展生存期(PFS)为29个月(95%CI 18-35个月)。cCRT前较低绝对淋巴细胞计数(ALC)和较高绝对中性粒细胞计数(ANC)与较差PFS相关,cCRT前中性粒细胞与淋巴细胞比值(NLR)升高是PFS最强预测因素。

要点

  • cCRT前较低ALC(HR 0.51,95%CI 0.32-0.82,p=0.02)与较差PFS相关。
  • cCRT前较高ANC(HR 1.14,95%CI 1.06-1.23,p=0.005)与较差PFS相关。
  • cCRT前NLR升高是PFS最强预测因素(HR 1.09,95%CI 1.05-1.14,p=0.0001)。

核心结论

  • 外周免疫细胞群的基线差异与接受cCRT和ICI的NSCLC患者的疾病结局相关。

研究设计与样本

  • 在单个癌症中心接受cCRT并至少接受1剂度伐利尤单抗的III期NSCLC患者被纳入分析。
  • 评估cCRT前、cCRT期间及ICI开始时外周血计数,并检验两个已发表模型估算免疫器官放疗剂量风险评分与疾病控制的关联。
  • 共评估113例患者,接受cCRT和度伐利尤单抗中位8.5个月。

主要发现

  • 中位PFS为29个月(95%CI 18-35个月)。
  • cCRT前较低ALC(HR 0.51,95%CI 0.32-0.82,p=0.02)和较高ANC(HR 1.14,95%CI 1.06-1.23,p=0.005)与较差PFS相关。
  • ALC最低值、ICI开始时ALC、ICI开始时ANC及cCRT前至最低值的ALC归一化变化均与PFS无显著关联(p=0.07-0.49)。
  • 两个放疗剂量模型的风险评分与PFS无显著关联(p=0.14,p=0.21),但与ALC最低值相关(p=0.001,p=0.002)。
  • cCRT前NLR较高是PFS最强预测因素(HR 1.09,95%CI 1.05-1.14,p=0.0001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of peripheral blood immune measures and radiation-induced lymphopenia on outcomes in non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiation (cCRT) and immune check point inhibition (ICI) has yet to be fully defined. METHODS: Stage III NSCLC patients treated with cCRT and ≥1 dose of durvalumab across a cancer center were examined. Peripheral blood counts were assessed pre-cCRT, during cCRT and at the start of ICI. These measures and risk-scores from two published models estimating radiation dose to immune-bearing organs were tested for association with disease control. RESULTS: We assessed 113 patients treated with cCRT and a median of 8.5 months of durvalumab. Median PFS was 29 months (95% CI 18-35 months). A lower pre-cCRT ALC (HR: 0.51 (95% CI: 0.32-0.82), p = 0.02) and a higher pre-cCRT ANC (HR: 1.14 (1.06-1.23), p = 0.005) were associated with poor PFS. Neither ALC nadir, ALC at ICI start, ANC at ICI start or the normalized change in ALC from pre-cCRT to nadir were significantly associated with PFS (p = 0.07-0.49). Also, risk scores from the two radiation-dose models were not associated with PFS (p = 0.14, p = 0.21) but were so with the ALC Nadir (p = 0.001, p = 0.002). A higher pre-cCRT NLR was the strongest predictor for PFS (HR: 1.09 (1.05-1.14), p = 0.0001). The 12-month PFS in patients with the bottom vs. top NLR tertile was 84% vs 46% (p = 0.000004). CONCLUSIONS: Baseline differences in peripheral immune cell populations are associated with disease outcomes in NSCLC patients treated with cCRT and ICI.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Thor M, Shepherd AF, Preeshagul I, et al. Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab. Radiother Oncol. 2021. PMID: 34942280. doi:10.1016/j.radonc.2021.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。